Skip to main content

Table 1 Patient characteristics at candidemia onset

From: Impact of host- and early treatment-related factors on mortality in ICU patients with candidemia: a bicentric retrospective observational study

VariablesTotal cohort
(n = 68)
30-day survivors
(n = 31)
30-day non-survivors
(n = 37)
P value
Male sex47 (69.1)22 (71.0)25 (67.6)0.798
Age (years)68.0 (61.0–76.0)68.0 (58.0–76.0)68.0 (63.0–76.0)0.782
Time from hospital admission to onset (days)24.5 (8.0–46.5)20.0 (6.0–42.0)26.0 (9.0–47.0)0.479
APACHE II score (points)21.0 (18.0–26.0)19.0 (13.0–24.0)23.0 (19.0–27.0)0.003
Comorbidities and prior treatment exposure
 Solid organ malignancy*11 (16.2)6 (19.4)5 (13.5)0.531
 Hematological malignancy*2 (2.9)0 (0.0)2 (5.4)0.496
 Solid organ transplantation4 (5.9)1 (3.2)3 (8.1)0.620
 Hematopoietic stem cell transplantation1 (1.5)0 (0.0)1 (2.7)1.000
 Liver disease14 (20.6)6 (19.4)8 (21.6)1.000
 Diabetes mellitus14 (20.6)4 (12.9)10 (27.0)0.229
 Autoimmune disease14 (20.6)7 (22.6)7 (18.9)0.769
 Neutropenia (< 500 cells/mm3)2 (2.9)0 (0.0)2 (5.4)0.496
 Abdominal surgery**18 (26.5)7 (22.6)11 (29.7)0.587
 Invasive mechanical ventilation56 (82.4)23 (74.2)33 (89.2)0.124
 Renal replacement therapy23 (33.8)7 (22.6)16 (43.2)0.122
 Total parenteral nutrition43 (63.2)18 (58.1)25 (67.6)0.458
 Antibiotic therapy (for ≥ 3 days) 65 (95.6)30 (96.8)35 (94.6)1.000
 Antifungal therapy (for ≥ 3 days) 6 (8.8)2 (6.5)4 (10.8)0.681
 Immunosuppressive therapy26 (38.2)9 (29.0)17 (46.0)0.211
Shock42 (61.8)17 (54.8)25 (67.6)0.324
Concurrent bacteremia22 (32.4)10 (32.3)12 (32.4)1.000
Breakthrough candidemia6 (8.8)2 (6.5)4 (10.8)0.681
  1. Values are given as n (%) or median (interquartile range). APACHE acute physiology and chronic health evaluation.
  2. *≤ 1 year before onset
  3. **≤ 3 months before onset
  4. ≤ 30 days before onset